Anaptysbio (ANAB) Total Current Liabilities (2016 - 2026)

Anaptysbio's Total Current Liabilities history runs 11 years deep, the most recent figure standing at $41.7 million for Q1 2026.

• Quarterly Total Current Liabilities fell 5.3% year-over-year to $41.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $41.7 million (down 5.3% YoY) and the FY2025 annual result came in at $38.6 million, down 14.98% from the prior year.
• Total Current Liabilities was $41.7 million for Q1 2026 at Anaptysbio, up from $38.6 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $45.4 million in Q4 2024 and bottomed at $19.8 million in Q1 2022.
• A 5-year average of $35.3 million and a median of $38.1 million in 2025 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Current Liabilities surged 109.51% — and 2025, when it slipped 14.98%.
• Anaptysbio's Total Current Liabilities stood at $26.1 million in 2022, then jumped by 43.71% to $37.4 million in 2023, then climbed by 21.33% to $45.4 million in 2024, then declined by 14.98% to $38.6 million in 2025, then rose by 7.97% to $41.7 million in 2026.
• Business Quant data shows ANAB's Total Current Liabilities at $41.7 million in Q1 2026, $38.6 million in Q4 2025, and $38.1 million in Q3 2025.